Can Alto Neuroscience turn an overlooked Parkinson’s drug into a major depression breakthrough?
Can Alto Neuroscience’s ALTO-207 change treatment-resistant depression care? Read what the new Phase 2b trial could mean for psychiatry.
Pharma & Biotech
Pharma & Biotech
Can Forlong Biotechnology’s FL115 poster at ASCO 2026 move the IL-15 story from scientific promise toward clinical relevance?
Forlong Biotechnology brings FL115 to ASCO 2026 with first-in-human solid tumor data. Read why the IL-15 story could matter beyond the poster.
Pharma & Biotech
Incyte brings Phase 3 tafasitamab data to ASCO 2026, but will frontMIND reshape first-line DLBCL treatment?
Incyte’s Phase 3 tafasitamab data are headed to ASCO 2026. Read what frontMIND could change for first-line DLBCL and what risks still remain.
Pharma & Biotech
Obsidian Therapeutics puts OBX-115 in the spotlight, but is this a real melanoma cell therapy inflection point?
Obsidian Therapeutics will present OBX-115 melanoma data at ASCO 2026. Read why the update matters for TIL therapy, scalability, and solid tumor strategy.
Pharma & Biotech
Is botensilimab finally ready for a bigger melanoma spotlight? Agenus bets on ASCO 2026
Agenus will unveil first Phase 2 botensilimab melanoma data at ASCO 2026. Read why the update could reshape sentiment around its checkpoint platform.
Pharma & Biotech
Convergent Therapeutics heads to ASCO 2026 with Phase 2 CONV01-alpha data in Lu-PSMA pretreated prostate cancer
Convergent Therapeutics will present Phase 2 CONV01-alpha data at ASCO 2026. Find out what this could mean for post-Lu-PSMA prostate cancer care.
Pharma & Biotech
Imneskibart enters the ASCO spotlight as Aulos Bioscience tests a smarter IL-2 strategy in melanoma
Aulos Bioscience will present new imneskibart melanoma data at ASCO 2026. Read what it could mean for IL-2 therapy and immuno-oncology.
Pharma & Biotech
From lorlatinib to PF-08634404, how Pfizer is trying to reshape its oncology story at ASCO 2026
Pfizer’s ASCO 2026 oncology data span lorlatinib, talazoparib, tucatinib and new pipeline assets. Read what the updates could change next.
Pharma & Biotech
Can Uqora’s Target expansion turn urinary health into a mainstream wellness category?
Uqora has entered Target stores and Target.com. Find out what this expansion means for urinary health retail and women’s wellness growth.
Pharma & Biotech
Can Genentech’s Enspryng become the first approved treatment for MOGAD after the Phase III METEOROID win?
Genentech’s Enspryng cut MOGAD relapse risk by 68% in Phase III. Read what the data could mean for regulators, clinicians, and the rare disease market.